Peripheral Arterial Disease (PAD) Treatment Devices

Boston Scientific Corp. CE mark Ranger Ranger Paclitaxel-coated PTA Balloon Cath

Boston Scientific received CE mark for the Ranger Paclitaxel-coated PTA Balloon Catheter. The technology is now in full European market launch. 

May 16, 2014 — In a move to expand significantly its portfolio of solutions for peripheral interventions, Boston Scientific Corp. has entered into a definitive agreement to acquire the interventional division of Bayer AG for $415 million...

The U.S. Food and Drug Administration (FDA) approved Abbott’s Supera Peripheral Stent System to treat people with blocked blood vessels in the upper leg caused by peripheral artery disease (PAD).

The U.S. Food and Drug Administration (FDA) cleared Cardiovascular Systems Inc.’s Diamondback 360 60 cm Peripheral Orbital Atherectomy Systems (OAS) for the treatment of peripheral arterial disease (PAD).

The first large prospective study to examine the effectiveness of laser atherectomy in the treatment of femoropopliteal in-stent restenosis (ISR) found that...
Covidien TurboHawk Clinical Study Directional Atherectomy Effective PAD Therapy
Directional atherectomy is safe and effective as a frontline therapy for the treatment of peripheral arterial disease (PAD), according to a landmark Covidien...
Directional atherectomy is safe and effective as a frontline therapy for the treatment of peripheral arterial disease (PAD), according to a landmark Covidien...
Teleflex Inc.’s subsidiary Hotspur Technologies Inc. received U.S. Food and Drug Administration (FDA) 510(k) clearance to market the Arrow GPSCath Balloon...
The Arrow GPSCath Balloon Dilatation Catheters is designed for use with 0.014-inch guidewires and in 150-cm length. These products enable a
Cordis Corp.'s Saber PTA (percutaneous transluminal angioplasty) dilatation catheter is for the treatment of patients with peripheral...
Cardiovascular Systems Inc.’s Diamondback 360 60 cm Peripheral Orbital Atherectomy Systems (OAS) are for the treatment of peripheral...
Boston Scientific's OffRoad Re-Entry Catheter System treats complete arterial blockages in the major arteries of the legs. ...

Articles

The first large prospective study to examine the effectiveness of laser atherectomy in the treatment of femoropopliteal in-stent restenosis (ISR) found that...
Covidien TurboHawk Clinical Study Directional Atherectomy Effective PAD Therapy
Directional atherectomy is safe and effective as a frontline therapy for the treatment of peripheral arterial disease (PAD), according to a landmark Covidien...
Directional atherectomy is safe and effective as a frontline therapy for the treatment of peripheral arterial disease (PAD), according to a landmark Covidien...
Boston Scientific Corp. CE mark Ranger Ranger Paclitaxel-coated PTA Balloon Cath
Boston Scientific received CE mark for the Ranger Paclitaxel-coated PTA Balloon Catheter. The technology is now in full European market launch. 

Video Center

By Dave Fornell, editor of DAIC Magazine The key take away messages from the 26th annual...
5 days 19 hours ago
As technology continues to advance for all diagnostic imaging modalities, it sometimes reminds me...
4 weeks 15 hours ago
The Society of Cardiovascular Computed Tomography (SCCT) annual meeting July 10-13 in San Diego...
9 weeks 5 days ago
This webinar explained the benefits of better access, productivity and revenue cycle efficiency in a modern cardiovascular information system (CVIS...
The webinar "PET/CT: A New Frontier" discusses potential benefits of digital relative to analog PET/CT. The session will discuss how digital PET can improve...
Centricity Cardio Enterprise, Cardiac PACS, Cardio PACS, CVIS
This webinar demonstrates the Centricity Cardio Enterprise Solution (CCE), a solution that can help cardiology departments and hospital administrators to...

Comparison Charts

Sorry there is no data available